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Psoriatic arthritis (PsA) is a common chronic inflammatory joint disorder that is closely associated with psoriatic skin disease. In a first genome-wide association study (GWAS) performed in close collaboration with our colleagues in the European Psoriatic Arthritis Consortium (PAGE), we were able to identify several genetic risk factors [1] . The finding of a PsA-associated genetic variant in the IL-17 signalling pathway seemed to be the most interesting with respect to its potential functional role in the pathogenesis of the disease. The mutant variant in the gene encoding the adapter protein Act-1 causes an amino acid exchange at the amino terminus of the protein thereby disrupting its interaction with the downstream adapter protein TRAF6 in the signalling cascade from the IL-17 receptor to NF-κB activation [1] . Presently, we are investigating the molecular mechanisms that might explain how this loss-of-function mutation might contribute to pro-inflammatory pathways in PsA pathogenesis. We will present our strategy to investigate the functional impact of the mutation on cytokine signalling in genotyped cell lines and report on initial results. In addition, an update will be given on recent progress that has been made in the elucidation of the genetic predisposition to psoriatic arthritis by the PAGE-consortium. Thus, association with a variant in the RUNX3 gene, rs4649038, was replicated in independent patients and controls [combined P value of 1.40×10(−8) by Cochran-MantelHaenszel test; odds ratio (OR) of 1.24] . Additional analyses based on linkage disequilibrium (LD) at RUNX3 revealed the most significant association in an LD block within the first intron of one isoform [2] . RUNX3 has already been implicated in susceptibility to ankylosing spondylitis (AS). However, the AS-associated risk allele is independent of the newly identified PsA-associated variant. Since the transcription factor RUNX-3 is involved in CD8+ T lymphocyte differentiation the identified genetic variants might have an impact on adaptive immune responses in the T cell-mediated diseases of PsA and plaque psoriasis. Background. Psoriasis is a chronic inflammatory disorder which is mainly orchestrated by proinflammatory T helper (Th) 1 and Th17 cells and commonly shows excellent therapeutic response to TNF-α antagonists.
TNF-α inhibitors induce restoration of peripheral regulatory T cells and reduction of pro-inflammatory T cells in psoriatic skin lesions
Methods. The present study comprehensively investigated the dynamics of peripheral blood and lesional skin T cell subsets in a cohort of 26 patients with severe plaque-type psoriasis upon treatment with the TNF-α blockers, adalimumab (n=13) and etanercept (n=13) over 28 weeks.
Results. All patients showed a marked clinical improvement documented by a significant decrease of PASI and DLQI. Anti-TNF-α treatment led to the restoration of afore diminished peripheral CD4+CD25+CD127low/-regulatory T cells (Treg) which was directly correlated to disease improvement. The numbers of Foxp3+ Treg cells in psoriatic skin lesions remained largely unaffected. Moreover, there was a significant decrease of the pro-inflammatory T cell infiltrate including Th17 cells in psoriatic skin after 8 weeks while peripheral effector T cell subsets remained unaffected. Conclusions. Thus, anti-TNF-α therapy exerts at least two anti-inflammatory effects, i.e. the induction of peripheral Treg cells and the selective inhibition of the pro-inflammatory T cell infiltrate in skin lesions. These findings suggest that the clinical efficacy of TNF-α blockers in psoriasis is also linked to the induction of disease-modifying Treg cells. Background. Cell migration is crucial for many important physiological and pathophysiological processes ranging from embryogenesis to tumor metastasis and rheumatoid arthritis. It requires the coordination of mechanical forces generated in different regions of the migrating cell. It has been proposed that stretch-activated, Ca2+ permeable channels are involved in mechano-signaling during cell migration. It is generally agreed upon that members of the classical transient receptor potential channel family (TRPC) are involved in chemotaxis and cell migration. Here, we investigated the role of TRPC-1 in fibroblasts migration and osteoclasts formation. Methods. For all in-vitro experiments, bone marrow macrophages (BMM) or fibroblasts were isolated from TRPC1-/-mice and corresponding wild type (WT) controls. For osteoclastogenesis BMMs were cultured in the presence of MCSF and RANKL. Using quantitative real-time PCR mRNA levels of TRPC1, Dc-Stamp and NFATC1 were analysed. Fibroblasts were stimulated with TNF alpha. Fibroblast vitality was analysed using a MTT assay. Time-lapse video microscopy was used to study osteoclast and fibroblast migration and osteoclast fusion. The intracellular Ca2+ concentration was measured ratiometrically with the fluorescent Ca2+ dye Fura-2, with and without mechanical stimulation. The skeletal phenotype of 16-week old mice was investigated by μCT-analyses of trabecular bone in the lumbar spine. Ovariectomy was performed on 12-week old sex-and aged-matched littermates as a model for human postmenopausal bone loss. Results. PCR analyses revealed that TRPC1 is hardly expressed in monocytes and pre-osteoclasts, but gets upregulated during osteoclast-differentiation. As seen in µCT analysis, TRPC1-/-mice showed no differences in bone phenotype compared to WT mice under physiological conditions. However, in the ovariectomy model of estrogendeficiency mediated bone loss, TRPC1-/-mice exhibited a reduced loss of trabecular bone volume (−28.9% in WT compared to −13.1% in TRPC1-/-) and bone tissue density (−3.2% in WT compared to +0.9% in TRPC1-/-) in LW5. Analysing the underlying signaling pathways, we found no differences in Ca2+-oscillations and store-operated calcium entries and no differences in NFATC1 expression. In time-lapse microscopy, however, we observed a reduced capacity of TRPC1-/-osteoclast precursors to migrate and to fuse, due to a reduced velocity, translocation and a reduced increase of cell area over time. The same migratory defect was observed for fibroblasts when mechanical stimulated, as well as fibroblasts stimulated with TNF alpha. The MTT assay revealed a decreased cell viability, which was even more pronounced under stimulation with TNF alpha. Conclusions. These results provide the evidence that TRPC1 is essential for migration of different cell types. Furthermore, it seems to be necessary for the fusion of osteoclasts. We have shown that the loss of TRPC1 while not affecting physiological bone turnover has a clear effect on accelerated bone loss as seen in estrogen deficiency. Additionally, TRPC1 might also play a role under inflammatory conditions. Thus, our data implicate that TRPC1 may represent a potential target for treating rapid osteoporotic bone loss like during rheumatoid arthritis. Background. Conventional disease-modifying anti-rheumatic drug (cDMARD) treatment is insufficient in some patients with rheumatoid arthritis (RA) thus requiring antagonists for TNF-α. Treatment with these agents demonstrates excellent remission rates documented with conventional radiographs and some magnetic resonance imaging (MRI) studies. The 3 Tesla technique allows higher spatial resolution as compared to 1.5 Tesla analysis. Especially early and thus prognostically relevant subchondral bone lesions might be detected more precisely. In addition, serum levels of soluble isoforms of vascular cell adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (sICAM-1) and endothelial-leukocyte adhesion molecule-1 (sELAM-1) might be serological indicators of synovial activation and may correlate to inflammatory infiltrates. Methods. Ongoing epidemiologic clinical pilot MRI study with 10 ACR/EULAR-positive, RA patients with inadequate response to two cDMARDs and thus an indication for etanercept (ETA) using the rheumatoid arthritis magnetic resonance imaging system (RAMRIS). These patients are compared to 10 patients adequately responding to cDMARDs. 3 Tesla MRI (PDSPAIR; T1 with and without contrast agent) using a multi-channel hand coil are performed at baseline, after four months, and after 12 months. MRI analyses include RAMRIS scoring with examination for synovitis, effusion, subchondral erosion, and also bone marrow edema. Data are compared to and correlated with, sVCAM-1, sICAM-1, sELAM-1 and clinical parameters such as DAS 28 (CRP). Results. Up to date, 10 ETA-treated patients were included. Data at baseline, after four months and after 12 months are available for 9 patients. The mean (±SD) total RAMRIS changed from 30.4 (±16.2) to 28.9 (±14.0) to 24.0 (±13.0) after one year. DAS 28 decreased from 3.8 (±1,2) to 3.1 (±1.0) and 2.4 (±0.9). Baseline data from 7 cDMARD patients (±SD; p-values compared to etanercept treatment) were as follows: RAMRIS 10,8 (±9.4; XX) and DAS 28 1.7 (±0.6; XX). None of the soluble adhesion molecule concentrations significantly changed over time. However, sVCAM was significantly higher in ETA patients at baseline (662.1 ng/ml ±132.7) as compared to cDMARD patients (225.0 ng/ml ±89.7) and healthy controls (356.1 ng/ml ±225.1). Background. Rheumatic diseases have been associated with accelerated atherosclerosis leading to an up to 3-fold increased risk for CV events such as myocardial infarction or stroke [1, 2] . The pathogenesis of atherosclerosis and RA involves similar pathomechanisms such as inflammatory cells and pro-inflammatory cytokines, e.g. tumor necrosis factor (TNF) [3] . Recent studies have shown that TNF antagonists may improve endothelial function in RA patients and therefore may minimize cardiovascular risk in RA [3, 4] . However, studies to confirm the cardiovascular effect of biologic agents on carotid wall thickness (CWT), plaque composition and inflammation or myocardial inflammation/fibrosis in RA do not exist. Methods. Single-blinded, cross sectional study to evaluate differences in carotid plaque burden, plaque composition and plaque inflammation as assessed by carotid MRI as well as the prevalence of myocardial inflammation/fibrosis and left ventricular dysfunction by cardiac MRI between two distinct patient groups: (i) 25 RA patients with newly initiated Etanercept treatment; (ii) 20 age-and gender matched patients with similar cardiovascular risk profile and without any evidence of systemic inflammatory disease. Longitudinal study design to assess the impact of 12-months of Etanercept therapy on the before mentioned MRI characteristics of cardiovascular involvement. Subjects in this trial should be at least 55 years of age to form a cohort at risk for cardiovascular disease. Imaging will be performed at 3T using a contrast-enhanced, multi-sequence protocol including dynamic contrast enhanced sequences of carotid plaques, cardiac late gadolinium enhancement (LGE) and T1-mapping (shMOLLI). Results. Primary imaging endpoints: differences in plaque burden, plaque inflammation, and presence of LGE in RA patients and control. Secondary imaging endpoints: MRI changes in mean and maximum %lipid/rich necrotic core, %fibrous tissue and %calcification of carotid plaques and in diffuse myocardial fibrosis (ECV fractions, T1 mapping), global LV function and LV volumes after 1 year of Etanercept treatment. Secondary clinical endpoints: changes of RA disease activity (DAS28), functional disability (HAQ disability index) and Framingham Risk Score. Conclusions. We want to assess the potential beneficial effect of TNF antagonist treatment on (i) early cardiac involvement by T1-mapping, functional cardiac analysis and LGE imaging and (ii) on plaque burden and plaque inflammation measurements by multi-sequence carotid MRI after 12 months of Etanercept treatment. Background. Psoriatic arthritis (PSA) is a chronic polyarthritis spectrum disorder strongly associated with cutaneous manifestations of psoriasis. There are several classification criteria for the diagnosis of PSA, the CASPAR classification criteria being established most recently. Its parameters cover aspects of psoriasis and arthritis as well as laboratory and radiological variables. Up to 30% of patients with psoriasis develop PSA. Imaging, especially magnetic resonance imaging (MRI) and ultrasonography, has allowed us to explain the relationships between enthesitis, synovitis (or the synovio-entheseal complex) and osteitis or bone oedema in PsA. The hrpqCT (µCT) technique enables us to detect periarticular bone alterations typical for RA (4) and PSA in a highly sensitive and specific manner. We also were able to detect even in asymptomatic patients (17/30 patients) with psoriasis periarticular bone alterations typical for PsA. These early alterations involve the whole circumference of the bone, leading to new bone formation. In the course of the disease, cortical thinning as a sign of subclinical osteoporosis occurs, presumably due to periosteal inflammation. Methods. Routine treatment (including the following reliable scores: PASI, DAS28, HAQ) of subjects will be complemented by a CT-scan with XtremeCT and a Hand MRI. Results. We have been able to enrol more than 30 patients so far. The analysis is still ongoing. Conclusions. In asymptomatic patients with psoriasis and PSA-like joint alterations measured by hrpq-CT, inflammation is detectable by MRI.
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Characterization of bone changes in ACPA-positive individuals without signs of arthritis compared to ACPA-negative, healthy subjects with HR-pQCT measurements of MCP joints Background. The decision to stop working in patients with early inflammatory arthritis (IA) is influenced by a wide range of factors besides arthritis disease activity. We assessed the association between patients' characteristics at arthritis onset and the consideration or decision to request disability pension. Methods. 501 gainfully employed patients ≤63 years of age enrolled in an early IA cohort (<6 months) were analyzed with respect to their consideration to go for early retirement within the first 12 months of rheumatologic care. Independent variables in multivariate logistic regression were sex, education, BMI, RF and/or ACPA serology, acute phase reactants (CRP and ESR normal/abnormal), tender and swollen joint counts (T/SJC28), and 12 physician reported common chronic conditions. Patient-reported parameters included pain, morning stiffness, fatigue, functional capacity (FFbH) and the first item of the Patient Health Questionnaire Depression scale (PHQ9): "Having little pleasure or interest in doing things during the last two weeks" (not at all, on several days, more than half of the days). The analysis was adjusted for age. Results. Patients (67% female) were 47±10 years old and had symptom duration of 13±7 weeks. 67% were RF and/or ACPA positive and 65% fulfilled the new ACR-EULAR RA criteria at baseline. At 12 months, 36 of the patients were considering applying for early retirement, 14 had applied and 12 had gone into early retirement. These 62 patients were about 6 years older and had significantly higher disease activity and severity, within the first year. However, none of the arthritis activity measures or any of the considered cardiovascular, metabolic or pulmonary diseases was associated with early retirement in multivariate analysis. Instead, the highest association was found with "having little pleasure or interest in doing things most of the days" (Tab. 1). Overall, 10.6% of the patients reported that problem; 30% of them were considering early retirement or had gone into. Conclusions. Whether or not patients with early arthritis are considering applying for disability pension depends more on mental conditions than on disease activity. Since one single depression statement was able to identify patients with an increased risk of early retirement, well-directed attention on the patient's well-being in the early stages of the disease may help the patients to remain in the labour force. Conclusions. This is one of the first studies which show functional joint-specific deficits during every day activities in patients who receive an initial anti-TNFα therapy. The limited stability and motor control might be due to limited joint integrity in the ankle joint. This is supported by the impaired push off function while walking. The next study step will show possible effects of the anti-TNFα therapy. 
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Background. Enthesitis-related arthritis is a juvenile idiopathic arthritis category, clinically related to the syndrome of undifferentiated spondyloarthropathy in adults. This study is intended to generate first evidence that treatment with etanercept is safe and effective in patients diagnosed with ERA-JIA who are able to acquire stable remission (inactive disease). Furthermore the stability of remission off medication in patients treated with etanercept will be demonstrated. Methods. This is a multi-center, open-labeled uncontrolled study of 24 weeks, followed by randomized, double-blind, placebo-controlled, withdrawal, parallel group treatment phase of further 24 weeks. In phase 1, a total of 40 patients with ERA-JIA are treated with etanercept (0.8 mg/kg up to a max of 50 mg sc per week) for 24 weeks. Patients who demonstrated at least a PedACR30 response in phase 2 will be randomised to two groups. Group 1 will continue treatment with etanercept for a maximum of further 24 weeks. Group 2 will receive placebo and will be followed up to observe the duration of a remission without therapy. The study phase 2 is terminated in case of a disease flare or after 24 weeks, whichever occurs earlier. Patients who flare in will enter phase 3, an open label extension phase. Patients who do not flare until week 48 will terminate the study. Results. The study is ongoing. 40 patients (67% male) have been recruited so far. 29 patients have reached week 24, 23 patients (77%) exhibited no tender joint, 28 patients (93%) no swollen joint, 23 patients (77%) no active joint, 18 patients (60%) showed a physician global indicating no disease activity, 28 patients (100%) had a normal ESR (<20 mm/h), 26 patients (87%) had a normal CRP (<5 mg/l), 25 patients (83%) had no tender enthesitis points. "Inactive disease" could be documented in 18 patients (60%). At week 24 97%/97%/87%/67%/63% of patients reached the PedACR30/50/70/90/100 criteria. So far, 1 patient did not reach ACR30 at week 24 and was not randomized. 29 patients were already randomized to receive placebo or etanercept, 10 flares occurred, 4 at week 28 and 4 at week 32, 18 patients reached week 48 without a flare. 2 patients were withdrawn from the study, one for allergic skin reaction, one for protocol violation. So far 91 adverse events have been observed, 12 cases with gastroenteritis, 9 with headache, 15 with upper airway infection, all other occurred less than 23 times. One serious adverse event, a posttraumatic renal hemorrhage, judges as not related to study drug was documented. Conclusion. In this ongoing study etanercept proved to be an effective therapeutic approach for patients with enthesitis-related arthritis (ERA-JIA) with a high rate of responders and a high rate of patients reaching "inactive disease" after 24 weeks of treatment. Since the study is still recruiting and blinded all results are preliminary. There was no new safety information. Background. Psychological stress, i.e. anticipatory anxiety concerning the prognosis of severe psoriasis, and mental disorders requiring special treatment, i.e. depression, are quite common concomitant symptoms in patients with chronic skin diseases. These should not only be seen as psychological reaction to a stressful situation but as a variety of conditions -the actual disease, the treatment, individual coping capacities and a vulnerability regarding mental illness -embedded in a complex structure. In addition, there are neurobiological, psychological and social interactions in patients with psoriasis and potential psychological and mental comorbidities that have not been fully understood yet. With this in mind the need to offer and provide for psychosocial support for psoriatic patients seems obvious. Methods. The main objective of this project is the detection of the most common mental disorders in psoriatic patients, as a first step to extend the knowledge about the variety of the individual disorders. Supplemented with the dermatological history and a physical examination, it should be possible to reveal correlations with disease severity and duration. Therefore, a multicentre consortium of psoriasis study centres in Germany will use the Patient Health Questionnaire (PHQ) supplemented by questions about medical history and dermatological disease data for psoriasis (PASI, DQLI) to conduct a survey with 200 patients with moderate or severe psoriasis.
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Results. The project starts in June 2013 and will be finished in summer 2014. Psoriatic arthritis (PsA) is a common chronic inflammatory joint disorder that is closely associated with psoriatic skin disease. Mostly, musculoskeletal involvement occurs after skin manifestations [1] . In early manifestations of PsA, changes in synovial vascularisation combined with increased expression of pro-angiotic factors appear [2] . Therefore, imaging principles for detection of changes in vascularisation can be used for early detection of joint disease and monitoring of disease activity. Xiralite® is a new fluorescence optical imaging device licensed for the detection of changes in microvascularisation of the hands. The method is tailored to the contrast agent ICG (indocyanine green; e.g. ICG-Pulsion®), which is approved in Europe as an agent for imaging diagnostics of microcirculation. After intravenous contrast administration, altered microcirculation of joints, tendons, bones and ligaments will be displayed due to an increased signal of the contrast agent [3] . Validity and sensitivity of Xiralite® will be examined in two different scenarios: Validity and sensitivity of Xiralite® in early detection of musculoskeletal involvement will be observed in patients with psoriasis having risk for development of musculoskeletal disease ( XCITING study). Therefore, Xiralite® imaging will be compared to clinical examination and ultrasound. In a second project, changes in disease activity will be measured by Xiralite and correlated to clinical examination/ultrasound in a homogeneous patient-group with a standardized treatment regimen with Etanercept (XPLORE study). Both projects will be conducted at 12 centres in Germany. The enrolment period has recently started. Objective. Clinical trials revealed that tumor necrosis factor alpha (TNF-α) blockade is more effective if administered with concomitant methotrexate (MTX). Based on an observation made when studying B cell subsets in patients with seropositive (sp) RA this study aimed to investigate the main mechanisms of action MTX exerts on the adaptive immune system. Methods. Peripheral blood samples of 78 spRA patients divided into four treatment groups (MTX: n=23, TNF-α-inhibitor: n=23, MTX/ TNF-α-inhibitor: n=17 and patients without MTX/TNF-α-inhibitor: n=15) were obtained and lymphocyte cell subsets were analyzed by multiparameter flow cytometry. To investigate the effect of MTX on B cell proliferation and differentiation in vitro cell culture assays were performed. Results. SpRA patients treated with MTX as monotherapy or in combination with TNF-blockade exhibited significantly lower frequencies and numbers of CD27highCD38high plasmablasts and a lower serum concentration of free light chains (FLC) compared to patients on anti-TNF-α monotherapy. MTX had no effect on in vitro proliferation, differentiation, and survival of purified B cells, but patients taking MTX showed significant lower numbers of CD45RO+ memory and CD44+CD62Llow effector T helper cells compared to patients not on MTX. Differentiated T helper cell subsets correlated significantly with plasmablast counts as did FLC and mutated citrullinated vimentin (MCV) antibody levels. In contrast to plasmablasts counts FLC concentrations were correlated with DAS28. Conclusion. Adding to the beneficial effect of TNF-α-inhibitors, MTX seems to correct the aberrant B cell activation in spRA indirectly by influencing the activation and differentiation of T helper cells. These findings argue for concomitant use of MTX with TNF-α-inhibitors to increase therapeutic efficacy. Background. Rheumatoid arthritis (RA) is the most common inflammatory/degenerative rheumatic disease of the joints with a worldwide prevalence of 0.5-1%, women being affected 3 times more often than men. Generally, people of all ages can suffer from RA, with a peak incidence between 35 and 45 years of age. Although the exact cause(s) of RA is unknown, autoimmunity plays a pivotal role in its chronicity and progression. A primary role in the pathogenesis of RA is taken on by synovial tissues, where activation and hyperproliferation of synovial fibroblasts leads to an inflammatory reaction. Attacking of the joints often progresses to destruction of the articular cartilage and bones, eventually resulting in ankylosis of the joints. Mainly signs and symptoms, blood tests and X-rays are used for RA diagnosis, but markers for early diagnosis or prognosis of therapy success are lacking. While various treatments are available to suppress the symptoms, disease-modifying anti-rheumatic drugs (DMARDs) are required to inhibit or halt the underlying immune process and delay or even prevent long-term damage. In the last few years, microRNAs (miRNAs) have emerged as new class of small endogenous, non-coding RNAs which regulate gene expression at the post-transcriptional level. These ~22-nt long double-stranded RNAs mostly bind to target mRNAs based on partial sequence complementarity, leading to translational repression or mRNA degradation. Cumulative data indicate that proper miRNA regulation is critical for prevention of autoimmunity and normal immune functions. miRNA molecules in serum are increasingly recognized as potential biomarkers for diagnosis and prognosis in a variety of diseases. Methods and results. If serum miRNAs are involved in response to RA treatment, we might identify a miRNA pattern that could allow estimation of e.g. the likelihood of successful treatment, i.e. to stop an unresponsive treatment as early as possible to minimize bone erosion. After establishing and optimizing serum miRNA isolation methods, the first step is the comparison of serum miRNA profiles of different untreated RA patient subgroups with that of healthy controls and osteoarthritis patients by next-generation sequencing analysis. In follow-up studies with appropriate serum RA patient samples, differentially expressed miRNAs before and after various RA treatment options will be investigated. Conclusions. Serum miRNA profiling might allow us to gain valuable insights into the molecular role of miRNAs in the development of rheumatic diseases and allow identification of diagnostic or prognostic small RNA biomarkers and potentially of therapeutic tools for RA. Background. TNF-inhibiting agents are firmly established as efficient therapy for plaque psoriasis with a highly favorable safety and tolerability profile. However, despite their common use, the therapeutic actions of these agents are not completely understood, and despite good overall clinical efficacy, a substantial proportion of the patient population fails to achieve a satisfactory clinical result. So far, the inter-individual differences in drug response cannot be predicted in patients. Methods. Fasting serum concentrations of 200 metabolites covering a biologically relevant panel of amino acids, sugars, acylcarnitines, and phospholipids, as well as genome-wide mRNA expression profiles generated from peripheral leukocytes and skin biopsies will be analysed in patients undergoing treatment with TNF-inhibiting agents in order to identify i) biomarkers that underlie variability in response to therapy, ii) metabolomic signatures associated with psoriasis and iii) treatment-specific metabolomic signatures. Results. Recruitment is ongoing, but recently published results from a comparable study on anti-IgE treatment in atopic dermatitis. Conclusions. Metabolic profiling can potentially assist the classification of patients and the prediction of treatment response as well as the investigation of mechanisms of drug action. Background. The minor allele of the single nucleotide polymorphism (SNP) in the IL4R gene, rs1805010, confers reduced IL-4 signaling and has previously been associated with an aggressive destructive course of rheumatoid arthritis (RA). IL-4 inhibits the development of Th17 cells, a cell population recently identified to be prominent in patients with RA and to associate with cartilage and bone destruction. Here, we investigated whether rs1805010 modulates Th17 cell development and, hence, subsequent clinical outcome in RA. Methods. Patients with early, active RA (n=90; DAS28 4.6±1.1) as well as controls [healthy subjects (n=24) and osteoarthritis patients (OA, n=15)] were genotyped. IL-17, IL-22 serum levels and Th17 cell frequencies were analyzed by ELISA and flow cytometry. Clinical and radiographic data were collected and evaluated at baseline and one year after disease onset. Results. 26% patients were homozygous for the major allele of rs1805010, 60% were heterozygous, and 14% were homozygous for the minor allele. RA patients homozygous for the minor allele demonstrated significantly higher clinical activity associated with the presence of erosions after one year of follow-up as compared to the other patients. The inhibitory effect of IL-4 on Th17 development in those patients was significantly less prominent. Accordingly, frequencies of Th17 cells and IL-17 and IL-22 serum levels were significantly increased. Conclusions. The data indicate that the minor allele of rs1805010 contributes to the increased Th17 cell frequency, enhanced clinical activity and accelerated radiographic progression in RA by rendering CD4 T cells from RA patients insensitive to the attenuating effect of IL-4 on Th17 cell development.
Prognosis and outcome
Determination of TNFα blocker serum levels and anti drug antibodies during long term treatment of rheumatoid arthritis patients and their association with clinical outcome and selected biomarkers
Sparing methotrexate in seropositive patients with rheumatoid arthritis results in a less stringent control of the adaptive immune system
Diagnostische und prognostische microRNAs in rheumatoider Arthritis
Differential analysis of metabolomic profiles in patients with
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The dynamics of IgG1 and IgG4 ACPA levels during therapy in rheumatoid arthritis Autoantibodies against citrullinated peptide antigens (ACPA) are of particular interest in rheumatoid arthritis (RA) as they substantially improved diagnosis and are indicative of immune tolerance gone astray. Recently, we could demonstrate that IgG1 and IgG4 are the most abundant immunoglobulin subclasses among two ACPA subpopulations, antibodies against cyclic citrullinated peptides (CCP) and mutated citrullinated vimentin (MCV), and that IgG4 ACPA level correlated with disease activity in two retrospectively investigated RA cohorts. In contrast, IgG1 ACPA levels were rather stable. However, there are conflicting results as to whether the levels of ACPA fluctuate with the disease status. Bos and colleagues have recently shown that IgG4 ACPA levels in RA patients decrease during treatment with tumor necrosis factor (TNF) blocking agents and that this decrease correlates with therapy response. This effect may be directly anti-TNF mediated or may be the result of an alleviated inflammatory reaction in the rheumatoid joints. In order to elucidate the mechanisms leading to a decrease in ACPA IgG4 levels we will investigate ACPA subclass titres in the course of TNF blocking as well as alternative biological or DMARD therapy. We started to collect serum samples of newly diagnosed RA patients who will be started on DMARDs and patients being started on different biologicals or changing the biological due to non-responsiveness. We will longitudinally follow up these patients at various time points to correlate ACPA levels with disease activity.
4.8
The impact of etanercept on retinal microcirculation and vascular dysfunction in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis Background. Increased mortality in chronic rheumatic diseases is mostly attributed to cardiovascular events (CVE). Assessment of endothelial dysfunction can help to identify patients at risk for major CVE. Studies have shown that the underlying endothelial dysfunction in rheumatoid arthritis is closely associated with inflammation. Only limited information is available whether the blockade of TNFα can restore endothelial function and decrease the incidence of cardiovascular events. Methods. Patients with active rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (SpA) were eligible for inclusion when anti-TNF-treatment was started. Study visits were performed at baseline, after one and three months. Clinical disease activity and inflammation marker were obtained. Systemic Coronary Risc Evaluation (SCORE) and measurement of intima media thickness (IMT) were performed to assess baseline cardiovascular (CV) risk. Endothelial function was measured by retinal vessel analysis (RVA) and peripheral tonometry (EndoPAT). Serum levels of pentraxin-3 were analysed as marker of endothelial function. Results. At this point 26 patients (11 RA, 6 PsA, 9 SpA) were analysed. Treatment was initiated with etanercept, certolizumab, infliximab, adalimumab or golimumab. Response to treatment after 3 month measured by ACR50 (RA and PsA) and ASAS20 (SpA) was found in 35% of RA-, 80% of PsA-and 63% of SpA patients. At baseline 7.7% (n=2) of patients had a risk for CV events >5%. IMT was <0.9 mm in all patients. Reactive hyperaemia index (RHI) assessed by EndoPAT was 1.87±0.49 (normal >1.67) . RVA showed differences of −0.03% (dilatation), −3.5% (constriction) and −2.1% (amplitude) compared to published data from age matched healthy individuals. One month after initiation of anti-TNF-treatment the increase in RHI was significantly higher in patients who did respond to treatment compared with nonresponders. RVA measurements did not reveal differences between responders and non-responders. Finally, serum levels of pentraxin-3 at baseline were 0.64±0.41 ng/ml (normal <0.65 ng/ml). A greater decrease of pentraxin-3 was observed in responders compared with nonresponders after one month, but did not reach the level of significance (p<0.05). Conclusions. Our data indicate that patients with active RA, PsA or SpA are at risk for cardiovascular events. Both, RVA and EndoPAT measurements indicate a greater risk in certain patients at baseline. After initiation of anti-TNF-treatment, responders show improvement of RHI in EndoPAT but no change in RVA. Overall, the data need to be interpreted with caution due to the relatively small number of investigated patients. joints (DAS28) >4 despite previous therapy with at least 2 DMARDS, one of which should be MTX] or diagnosed with osteoarthritis (healthy control) will be eligible for this study. Stool and blood samples will be collected from patients receiving MTX (n=20) or anti-TNF agents (Adalimumab, Etanercept; n=20 each) at various time points before and after drug-administration. For analysis of the intestinal microbiota microbial DNA will be isolated and 16s rRNA will be subjected to 454-pyrosequencing and further analysis as described before. In short, intestinal microbiota will be analyzed according to microbial richness and abundance according (i) intraindividual time dependent changes after treatment and (ii) interindividual changes according to treatment groups. Results. Results are expected to give rise to the questions whether intestinal dysbiosis is present in patients with rheumatoid arthritis, therapeutic cytokine neutralization by anti TNF-agents shapes the gut microbiota, the impact of therapeutic cytokine neutralization by anti TNF-agents on gut microbiota correlates with response/non-response in rheumatoid arthritis? These data could generate insights into the role of dysbiosis in rheumatoid arthritis and the role of gut microbial determinants that predict therapy response in chronic inflammatory disorders in general.
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5.2
Comparison of risk and patient-related benefit of treatment with etanercept in elderly patients with rheumatoid arthritis (acronym: CORELA) Background. Initial manifestation of rheumatoid arthritis (RA) is after the age of 60 years in one third of patients. The TNF-α inhibitor etanercept (ETA) has been shown to significantly reduce disease activity in RA patients not responding to treatment with traditional disease-modifying anti-rheumatic drugs (DMARD) and to enhance the functional capacity after inhibition of inflammation. However, little is known about the influence on patient-reported outcomes such as quality of life and fatigue in elderly patients due to the fact that patients in phase-III studies are usually younger. Furthermore, there is only limited data whether treatment with immunomodulatory drugs leads to a higher rate of therapy-related adverse events in elderly patients. The aim of this non-interventional observation study is to evaluate the effect of ETA on quality of life, fatigue, and quality of sleep in elderly patients, and to compare the results with clinical disease activity determined by DAS 28, as well as safety parameters [adverse events (AE) and serious AE].
Methods. There are two study groups: 1. patients beginning with ETA and/or DMARD, and 2. patients beginning with only DMARD therapy. The study duration per patient is one year: screening and baseline visit, visit 1 after 6 months (T1), and visit 2 after 12 months (T2). According to the sample size calculation, 65 patients per group are needed (130 patients in total). Main inclusion criteria: 1. patients older than 60 years, 2. RA according to ACR criteria from 1987, 3. treatment with ETA and/or DMARD, as indicated according to DGRh. The primary endpoint of this study is the long-term effect of ETA on quality of life, fatigue, and quality of sleep assessed by validated questionnaires after V1 and V2. Secondary end points are (all from T0 to T1 and T2) 1. change in disease activity by DAS28 and CDAI, 2. functional capacity (HAQ), 3. pain, 4. eating behaviour, 5. emotional state, 6. ACR20, ACR50, ACR70. Safety aspects are assessed as AE and SAE from T0 to T1 and T2 using a patient diary. Results. 31 study sites across Germany participate in this project. Patient recruitment started in July 2012. So far, 22 patients have been included in the study, 10 in the ETA group, and 12 in the DMARD group. Recruitment is still ongoing to meet the goal of 65 patients per group. Registration of new study sites is still possible.
Conclusions. This study aims at evaluating the effect of ETA on quality of life, fatigue, and quality of sleep in elderly patients. Recruitment is still ongoing; to meet the goal of 130 patients, only three more patients per study site need to be recruited. 
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